D&O Ongoing Disclosure Notices (multiple)

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and ASX
Name of listed issuer: Oceania Healthcare Limited
Date this disclosure made: 29 June 2021
Date of last disclosure: 23 April 2021

Director or senior manager giving disclosure
Full name(s): Elizabeth Coutts
Name of listed issuer: Oceania Healthcare Limited
Name of related body corporate (if applicable): N/A
Position held in listed issuer: Director

Summary of acquisition or disposal of relevant interest (excluding derivatives)
Class of affected quoted financial products: Ordinary shares
Nature of the affected relevant interest(s): Beneficial owner of shares
For that relevant interest -
Number held in class before acquisition or disposal: 1,545,903
Number held in class after acquisition or disposal: 1,569,025
Current registered holder(s): New share issue
Registered holder(s) once transfers are registered: Custodial Services Limited

Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative: N/A
Class of underlying financial products: N/A
Details of affected derivative -
The notional value of the derivative (if any) or the notional
amount of underlying financial products (if any):
N/A
A statement as to whether the derivative is cash settled or
physically settled:
N/A
Maturity date of the derivative (if any): N/A
Expiry date of the derivative (if any): N/A
The price specified in the terms of the derivative (if any): N/A
Any other details needed to understand how the amount of
the consideration payable under the derivative or the value
N/A

of the derivative is affected by the value of the underlying
financial products:
For that derivative: -
Parties to the derivative: N/A
If the director or senior manager is not a party to the
derivative, the nature of the relevant interest in the
derivative:
N/A

Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: 1
Details of transactions requiring disclosure -
Date of transaction: 22 June 2021
Nature of transaction: Acquisition of 23,122 ordinary
shares in Oceania Healthcare
Limited in accordance with the
Dividend Reinvestment Plan
2019
Name of any other party or parties to the transaction (if
known):

The consideration, expressed in New Zealand dollars, paid
or received for the acquisition or disposal. If the
consideration was not in cash and cannot be readily
converted into a cash value, describe the consideration:
$32,463.96
Number of financial products to which the transaction
related:
23,122
If the issuer has a financial products trading policy that
prohibits directors or senior managers from trading during
any period without written clearance (a closed period)
include the following details -

Whether relevant interests were acquired or disposed of
during a closed period:
No
Whether prior written clearance was provided to allow the
acquisition or disposal to proceed during the closed period:
N/A
Date of the prior written clearance (if any): N/A

Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products: N/A
Nature of relevant interest: N/A
For that relevant interest -
Number held in class: N/A
Current registered holder(s): N/A
For a derivative relevant interest -
Type of derivative: N/A
Details of derivative -

The notional value of the derivative (if any) or the notional
amount of underlying financial products (if any):
N/A
A statement as to whether the derivative is cash settled or
physically settled:
N/A
Maturity date of the derivative (if any): N/A
Expiry date of the derivative (if any): N/A
The price’s specified terms (if any): N/A
Any other details needed to understand how the amount of
the consideration payable under the derivative or the value
of the derivative is affected by the value of the underlying
financial products:
N/A
For that derivative relevant interest:
Parties to the derivative: N/A
If the director or senior manager is not a party to the
derivative, the nature of the relevant interest in the
derivative:
N/A

Certification
I certify that, to the best of my knowledge and belief, the
information contained in this disclosure is correct and that I
am duly authorised to make this disclosure by all persons
for whom it is made.

Signature of director or officer:

Date of signature:
or
Signature of person authorised to sign on behalf of director
or officer:


Date of signature: 29 June 2021
Name and title of authorised person: Anna Thorburn
Group General Counsel

---

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and ASX
Name of listed issuer: Oceania Healthcare Limited
Date this disclosure made: 29 June 2021
Date of last disclosure: 23 April 2021

Director or senior manager giving disclosure
Full name(s): Alan Isaac
Name of listed issuer: Oceania Healthcare Limited
Name of related body corporate (if applicable): N/A
Position held in listed issuer: Director

Summary of acquisition or disposal of relevant interest (excluding derivatives)
Class of affected quoted financial products: Ordinary shares
Nature of the affected relevant interest(s):
Beneficial owner of shares
acquired pursuant to the Dividend
Reinvestment Plan 2019
For that relevant interest -
Number held in class before acquisition or disposal: 155,409
Number held in class after acquisition or disposal: 156,966
Current registered holder(s): New share issue
Registered holder(s) once transfers are registered: Alan Raymond Isaac, Andrew
John Dinsdale and Alasdair
Donald McBeth as trustees of
Isaac Family Trust

Summary of acquisition or disposal of relevant interest (excluding derivatives)
Class of affected quoted financial products: Ordinary shares
Nature of the affected relevant interest(s):
Registered and beneficial owner
of shares acquired pursuant to the
Dividend Reinvestment Plan 2019
For that relevant interest -
Number held in class before acquisition or disposal: 130,286
Number held in class after acquisition or disposal: 131,591
Current registered holder(s): New share issue

Registered holder(s) once transfers are registered: Alan Raymond Isaac

Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative: N/A
Class of underlying financial products: N/A
Details of affected derivative -
The notional value of the derivative (if any) or the notional
amount of underlying financial products (if any):
N/A
A statement as to whether the derivative is cash settled or
physically settled:
N/A
Maturity date of the derivative (if any): N/A
Expiry date of the derivative (if any): N/A
The price specified in the terms of the derivative (if any): N/A
Any other details needed to understand how the amount of
the consideration payable under the derivative or the value
of the derivative is affected by the value of the underlying
financial products:
N/A
For that derivative: -
Parties to the derivative: N/A
If the director or senior manager is not a party to the
derivative, the nature of the relevant interest in the
derivative:
N/A

Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: 1
Details of transactions requiring disclosure -
Date of transaction: 22 June 2021
Nature of transaction: Acquisition of 1,557 ordinary
shares in Oceania Healthcare
Limited in accordance with the
Dividend Reinvestment Plan 2019
Name of any other party or parties to the transaction (if
known):

The consideration, expressed in New Zealand dollars, paid
or received for the acquisition or disposal. If the
consideration was not in cash and cannot be readily
converted into a cash value, describe the consideration:
$2,186.61
Number of financial products to which the transaction
related:
1,557
If the issuer has a financial products trading policy that
prohibits directors or senior managers from trading during
any period without written clearance (a closed period)
include the following details -

Whether relevant interests were acquired or disposed of
during a closed period:
No

Whether prior written clearance was provided to allow the
acquisition or disposal to proceed during the closed period:
N/A
Date of the prior written clearance (if any): N/A

Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: 1
Details of transactions requiring disclosure -
Date of transaction: 22 June 2021
Nature of transaction: Acquisition of 1,305 ordinary
shares in Oceania Healthcare
Limited in accordance with the
Dividend Reinvestment Plan 2019
Name of any other party or parties to the transaction (if
known):

The consideration, expressed in New Zealand dollars, paid
or received for the acquisition or disposal. If the
consideration was not in cash and cannot be readily
converted into a cash value, describe the consideration:
$1,833.13
Number of financial products to which the transaction
related:
1,305
If the issuer has a financial products trading policy that
prohibits directors or senior managers from trading during
any period without written clearance (a closed period)
include the following details -

Whether relevant interests were acquired or disposed of
during a closed period:
No
Whether prior written clearance was provided to allow the
acquisition or disposal to proceed during the closed period:
N/A
Date of the prior written clearance (if any): N/A

Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products: Ordinary shares
Nature of relevant interest: Registered and beneficial owner
of shares
For that relevant interest -
Number held in class: 15,000
Current registered holder(s): Mary Isaac
For a derivative relevant interest -
Type of derivative: N/A
Details of derivative -
The notional value of the derivative (if any) or the notional
amount of underlying financial products (if any):
N/A
A statement as to whether the derivative is cash settled or
physically settled:
N/A
Maturity date of the derivative (if any): N/A

Expiry date of the derivative (if any): N/A
The price’s specified terms (if any): N/A
Any other details needed to understand how the amount of
the consideration payable under the derivative or the value
of the derivative is affected by the value of the underlying
financial products:
N/A
For that derivative relevant interest:
Parties to the derivative: N/A
If the director or senior manager is not a party to the
derivative, the nature of the relevant interest in the
derivative:
N/A

Certification
I certify that, to the best of my knowledge and belief, the
information contained in this disclosure is correct and that I
am duly authorised to make this disclosure by all persons
for whom it is made.

Signature of director or officer:

Date of signature:
or
Signature of person authorised to sign on behalf of director
or officer:


Date of signature: 29 June 2021
Name and title of authorised person: Anna Thorburn
Group General Counsel

---

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and ASX
Name of listed issuer: Oceania Healthcare Limited
Date this disclosure made: 29 June 2021
Date of last disclosure: 23 April 2021

Director or senior manager giving disclosure
Full name(s): Gregory Tomlinson
Name of listed issuer: Oceania Healthcare Limited
Name of related body corporate (if applicable): N/A
Position held in listed issuer: Director

Summary of acquisition or disposal of relevant interest (excluding derivatives)
Class of affected quoted financial products: Ordinary shares
Nature of the affected relevant interest(s):
Gregory Tomlinson has the power
to control the exercise of a right to
vote attached to the product and
the power to control the
acquisition and disposal of the
product.
For that relevant interest -
Number held in class before acquisition or disposal: 20,248,275
Number held in class after acquisition or disposal: 20,551,133
Current registered holder(s): New share issue
Registered holder(s) once transfers are registered: Tomlinson Group Investments
Limited

Summary of acquisition or disposal of relevant interest (excluding derivatives)
Class of affected quoted financial products: Ordinary shares
Nature of the affected relevant interest(s): Harrogate Trustee Limited or its
directors are accustomed to act in
accordance with Gregory
Tomlinson's wishes in relation to a
relevant interest held by
Harrogate Trustee Limited.
For that relevant interest -
Number held in class before acquisition or disposal: 3,749,265

Number held in class after acquisition or disposal: 3,805,343
Current registered holder(s): New share issue
Registered holder(s) once transfers are registered: Harrogate Trustee Limited

Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative: N/A
Class of underlying financial products: N/A
Details of affected derivative -
The notional value of the derivative (if any) or the notional
amount of underlying financial products (if any):
N/A
A statement as to whether the derivative is cash settled or
physically settled:
N/A
Maturity date of the derivative (if any): N/A
Expiry date of the derivative (if any): N/A
The price specified in the terms of the derivative (if any): N/A
Any other details needed to understand how the amount of
the consideration payable under the derivative or the value
of the derivative is affected by the value of the underlying
financial products:
N/A
For that derivative: -
Parties to the derivative: N/A
If the director or senior manager is not a party to the
derivative, the nature of the relevant interest in the
derivative:
N/A

Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: 1
Details of transactions requiring disclosure -
Date of transaction: 22 June 2021
Nature of transaction: Acquisition of 302,858 ordinary
shares in Oceania Healthcare
Limited by Tomlinson Group
Investments Limited in
accordance with the Dividend
Reinvestment Plan 2019
Name of any other party or parties to the transaction (if
known):

The consideration, expressed in New Zealand dollars, paid
or received for the acquisition or disposal. If the
consideration was not in cash and cannot be readily
converted into a cash value, describe the consideration:
$425,213.78
Number of financial products to which the transaction
related:
302,858
If the issuer has a financial products trading policy that
prohibits directors or senior managers from trading during

any period without written clearance (a closed period)
include the following details -
Whether relevant interests were acquired or disposed of
during a closed period:
No
Whether prior written clearance was provided to allow the
acquisition or disposal to proceed during the closed period:
N/A
Date of the prior written clearance (if any): N/A

Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: 1
Details of transactions requiring disclosure -
Date of transaction: 22 June 2021
Nature of transaction: Acquisition of 56,078 ordinary
shares in Oceania Healthcare
Limited by Tomlinson Group
Investments Limited in
accordance with the Dividend
Reinvestment Plan 2019
Name of any other party or parties to the transaction (if
known):

The consideration, expressed in New Zealand dollars, paid
or received for the acquisition or disposal. If the
consideration was not in cash and cannot be readily
converted into a cash value, describe the consideration:
$78,734.57
Number of financial products to which the transaction
related:
56,078
If the issuer has a financial products trading policy that
prohibits directors or senior managers from trading during
any period without written clearance (a closed period)
include the following details -

Whether relevant interests were acquired or disposed of
during a closed period:
No
Whether prior written clearance was provided to allow the
acquisition or disposal to proceed during the closed period:
N/A
Date of the prior written clearance (if any): N/A

Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products: N/A
Nature of relevant interest: N/A
For that relevant interest -
Number held in class: N/A
Current registered holder(s): N/A
For a derivative relevant interest -
Type of derivative: N/A
Details of derivative -

The notional value of the derivative (if any) or the notional
amount of underlying financial products (if any):
N/A
A statement as to whether the derivative is cash settled or
physically settled:
N/A
Maturity date of the derivative (if any): N/A
Expiry date of the derivative (if any): N/A
The price’s specified terms (if any): N/A
Any other details needed to understand how the amount of
the consideration payable under the derivative or the value
of the derivative is affected by the value of the underlying
financial products:
N/A
For that derivative relevant interest:
Parties to the derivative: N/A
If the director or senior manager is not a party to the
derivative, the nature of the relevant interest in the
derivative:
N/A

Certification
I certify that, to the best of my knowledge and belief, the
information contained in this disclosure is correct and that I
am duly authorised to make this disclosure by all persons
for whom it is made.

Signature of director or officer:

Date of signature:
or
Signature of person authorised to sign on behalf of director
or officer:


Date of signature: 29 June 2021
Name and title of authorised person: Anna Thorburn
Group General Counsel

---

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and ASX
Name of listed issuer: Oceania Healthcare Limited
Date this disclosure made: 29 June 2021
Date of last disclosure: 23 April 2021

Director or senior manager giving disclosure
Full name(s): Kerry Prendergast
Name of listed issuer: Oceania Healthcare Limited
Name of related body corporate (if applicable): N/A
Position held in listed issuer: Director

Summary of acquisition or disposal of relevant interest (excluding derivatives)
Class of affected quoted financial products: Ordinary shares
Nature of the affected relevant interest(s):
Registered and beneficial owner
of shares acquired pursuant to the
Dividend Reinvestment Plan 2019
For that relevant interest -
Number held in class before acquisition or disposal: 342,970
Number held in class after acquisition or disposal: 346,407
Current registered holder(s): New share issue
Registered holder(s) once transfers are registered: Kerry Prendergast

Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative: N/A
Class of underlying financial products: N/A
Details of affected derivative -
The notional value of the derivative (if any) or the notional
amount of underlying financial products (if any):
N/A
A statement as to whether the derivative is cash settled or
physically settled:
N/A
Maturity date of the derivative (if any): N/A
Expiry date of the derivative (if any): N/A
The price specified in the terms of the derivative (if any): N/A

Any other details needed to understand how the amount of
the consideration payable under the derivative or the value
of the derivative is affected by the value of the underlying
financial products:
N/A
For that derivative: -
Parties to the derivative: N/A
If the director or senior manager is not a party to the
derivative, the nature of the relevant interest in the
derivative:
N/A

Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: 1
Details of transactions requiring disclosure -
Date of transaction: 22 June 2021
Nature of transaction: Acquisition of 3,437 ordinary
shares in Oceania Healthcare
Limited in accordance with the
Dividend Reinvestment Plan 2019
Name of any other party or parties to the transaction (if
known):

The consideration, expressed in New Zealand dollars, paid
or received for the acquisition or disposal. If the
consideration was not in cash and cannot be readily
converted into a cash value, describe the consideration:
$4,825.59
Number of financial products to which the transaction
related:
3,437
If the issuer has a financial products trading policy that
prohibits directors or senior managers from trading during
any period without written clearance (a closed period)
include the following details -

Whether relevant interests were acquired or disposed of
during a closed period:
No
Whether prior written clearance was provided to allow the
acquisition or disposal to proceed during the closed period:
N/A
Date of the prior written clearance (if any): N/A

Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products: N/A
Nature of relevant interest: N/A
For that relevant interest -
Number held in class: N/A
Current registered holder(s): N/A
For a derivative relevant interest -
Type of derivative: N/A
Details of derivative -

The notional value of the derivative (if any) or the notional
amount of underlying financial products (if any):
N/A
A statement as to whether the derivative is cash settled or
physically settled:
N/A
Maturity date of the derivative (if any): N/A
Expiry date of the derivative (if any): N/A
The price’s specified terms (if any): N/A
Any other details needed to understand how the amount of
the consideration payable under the derivative or the value
of the derivative is affected by the value of the underlying
financial products:
N/A
For that derivative relevant interest:
Parties to the derivative: N/A
If the director or senior manager is not a party to the
derivative, the nature of the relevant interest in the
derivative:
N/A

Certification
I certify that, to the best of my knowledge and belief, the
information contained in this disclosure is correct and that I
am duly authorised to make this disclosure by all persons
for whom it is made.

Signature of director or officer:

Date of signature:
or
Signature of person authorised to sign on behalf of director
or officer:


Date of signature: 29 June 2021
Name and title of authorised person: Anna Thorburn
Group General Counsel

---

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and ASX
Name of listed issuer: Oceania Healthcare Limited
Date this disclosure made: 29 June 2021
Date of last disclosure: 2 March 2021

Director or senior manager giving disclosure
Full name(s): Sally Evans
Name of listed issuer: Oceania Healthcare Limited
Name of related body corporate (if applicable): N/A
Position held in listed issuer: Director

Summary of acquisition or disposal of relevant interest (excluding derivatives)
Class of affected quoted financial products: Ordinary shares
Nature of the affected relevant interest(s):
Registered and beneficial owner
of shares
For that relevant interest -
Number held in class before acquisition or disposal: 65,180
Number held in class after acquisition or disposal: 66,008
Current registered holder(s): New share issue
Registered holder(s) once transfers are registered: Sally Evans

Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative: N/A
Class of underlying financial products: N/A
Details of affected derivative -
The notional value of the derivative (if any) or the notional
amount of underlying financial products (if any):
N/A
A statement as to whether the derivative is cash settled or
physically settled:
N/A
Maturity date of the derivative (if any): N/A
Expiry date of the derivative (if any): N/A
The price specified in the terms of the derivative (if any): N/A

Any other details needed to understand how the amount of
the consideration payable under the derivative or the value
of the derivative is affected by the value of the underlying
financial products:
N/A
For that derivative: -
Parties to the derivative: N/A
If the director or senior manager is not a party to the
derivative, the nature of the relevant interest in the
derivative:
N/A

Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: 1
Details of transactions requiring disclosure -
Date of transaction: 22 June 2021
Nature of transaction: Acquisition of 828 ordinary shares
in Oceania Healthcare Limited in
accordance with the Dividend
Reinvestment Plan 2019
Name of any other party or parties to the transaction (if
known):

The consideration, expressed in New Zealand dollars, paid
or received for the acquisition or disposal. If the
consideration was not in cash and cannot be readily
converted into a cash value, describe the consideration:
$1,163.46
Number of financial products to which the transaction
related:
828
If the issuer has a financial products trading policy that
prohibits directors or senior managers from trading during
any period without written clearance (a closed period)
include the following details -

Whether relevant interests were acquired or disposed of
during a closed period:
No
Whether prior written clearance was provided to allow the
acquisition or disposal to proceed during the closed period:
N/A
Date of the prior written clearance (if any): N/A

Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products: N/A
Nature of relevant interest: N/A
For that relevant interest -
Number held in class: N/A
Current registered holder(s): N/A
For a derivative relevant interest -
Type of derivative: N/A
Details of derivative -

The notional value of the derivative (if any) or the notional
amount of underlying financial products (if any):
N/A
A statement as to whether the derivative is cash settled or
physically settled:
N/A
Maturity date of the derivative (if any): N/A
Expiry date of the derivative (if any): N/A
The price’s specified terms (if any): N/A
Any other details needed to understand how the amount of
the consideration payable under the derivative or the value
of the derivative is affected by the value of the underlying
financial products:
N/A
For that derivative relevant interest:
Parties to the derivative: N/A
If the director or senior manager is not a party to the
derivative, the nature of the relevant interest in the
derivative:
N/A

Certification
I certify that, to the best of my knowledge and belief, the
information contained in this disclosure is correct and that I
am duly authorised to make this disclosure by all persons
for whom it is made.

Signature of director or officer:

Date of signature:
or
Signature of person authorised to sign on behalf of director
or officer:


Date of signature: 29 June 2021
Name and title of authorised person: Anna Thorburn
Group General Counsel

---

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and ASX
Name of listed issuer: Oceania Healthcare Limited
Date this disclosure made: 29 June 2021
Date of last disclosure: 23 April 2021

Director or senior manager giving disclosure
Full name(s): Brent Pattison
Name of listed issuer: Oceania Healthcare Limited
Name of related body corporate (if applicable): N/A
Position held in listed issuer: Chief Executive Officer

Summary of acquisition or disposal of relevant interest (excluding derivatives)
Class of affected quoted financial products: Ordinary shares
Nature of the affected relevant interest(s):
Registered and beneficial owner
of shares acquired pursuant to the
Dividend Reinvestment Plan 2019
For that relevant interest -
Number held in class before acquisition or disposal: 223,085
Number held in class after acquisition or disposal: 225,320
Current registered holder(s): New share issue
Registered holder(s) once transfers are registered: Brent Pattison

Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative: N/A
Class of underlying financial products: N/A
Details of affected derivative -
The notional value of the derivative (if any) or the notional
amount of underlying financial products (if any):
N/A
A statement as to whether the derivative is cash settled or
physically settled:
N/A
Maturity date of the derivative (if any): N/A
Expiry date of the derivative (if any): N/A
The price specified in the terms of the derivative (if any): N/A

Any other details needed to understand how the amount of
the consideration payable under the derivative or the value
of the derivative is affected by the value of the underlying
financial products:
N/A
For that derivative: -
Parties to the derivative: N/A
If the director or senior manager is not a party to the
derivative, the nature of the relevant interest in the
derivative:
N/A

Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: 1
Details of transactions requiring disclosure -
Date of transaction: 22 June 2021
Nature of transaction: Acquisition of 2,235 ordinary
shares in Oceania Healthcare
Limited in accordance with the
Dividend Reinvestment Plan 2019
Name of any other party or parties to the transaction (if
known):

The consideration, expressed in New Zealand dollars, paid
or received for the acquisition or disposal. If the
consideration was not in cash and cannot be readily
converted into a cash value, describe the consideration:
$3,138.81
Number of financial products to which the transaction
related:
2,235
If the issuer has a financial products trading policy that
prohibits directors or senior managers from trading during
any period without written clearance (a closed period)
include the following details -

Whether relevant interests were acquired or disposed of
during a closed period:
No
Whether prior written clearance was provided to allow the
acquisition or disposal to proceed during the closed period:
N/A
Date of the prior written clearance (if any): N/A

Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products: Ordinary shares
Nature of relevant interest:
Beneficial interest in shares
issued under the terms of the
Oceania Healthcare Employee
Share Scheme, under which
shares are held by OCA
Employees Trustee Limited
For that relevant interest -
Number held in class: 766
Current registered holder(s): OCA Employees Trustee Limited

For a derivative relevant interest -
Type of derivative: N/A
Details of derivative -
The notional value of the derivative (if any) or the notional
amount of underlying financial products (if any):
N/A
A statement as to whether the derivative is cash settled or
physically settled:
N/A
Maturity date of the derivative (if any): N/A
Expiry date of the derivative (if any): N/A
The price’s specified terms (if any): N/A
Any other details needed to understand how the amount of
the consideration payable under the derivative or the value
of the derivative is affected by the value of the underlying
financial products:
N/A
For that derivative relevant interest:
Parties to the derivative: N/A
If the director or senior manager is not a party to the
derivative, the nature of the relevant interest in the
derivative:
N/A

Certification
I certify that, to the best of my knowledge and belief, the
information contained in this disclosure is correct and that I
am duly authorised to make this disclosure by all persons
for whom it is made.

Signature of director or officer:
Date of signature:
or
Signature of person authorised to sign on behalf of director
or officer:


Date of signature: 29 June 2021
Name and title of authorised person: Anna Thorburn
Group General Counsel

---

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and ASX
Name of listed issuer: Oceania Healthcare Limited
Date this disclosure made: 29 June 2021
Date of last disclosure: 23 April 2021

Director or senior manager giving disclosure
Full name(s): Anna Thorburn
Name of listed issuer: Oceania Healthcare Limited
Name of related body corporate (if applicable): N/A
Position held in listed issuer: Group General Counsel

Summary of acquisition or disposal of relevant interest (excluding derivatives)
Class of affected quoted financial products: Ordinary shares
Nature of the affected relevant interest(s):
Registered and beneficial owner
of shares acquired pursuant to the
Dividend Reinvestment Plan 2019
For that relevant interest -
Number held in class before acquisition or disposal: 215,137
Number held in class after acquisition or disposal: 217,292
Current registered holder(s): New share issue
Registered holder(s) once transfers are registered: Anna Thorburn

Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative: N/A
Class of underlying financial products: N/A
Details of affected derivative -
The notional value of the derivative (if any) or the notional
amount of underlying financial products (if any):
N/A
A statement as to whether the derivative is cash settled or
physically settled:
N/A
Maturity date of the derivative (if any): N/A
Expiry date of the derivative (if any): N/A
The price specified in the terms of the derivative (if any): N/A

Any other details needed to understand how the amount of
the consideration payable under the derivative or the value
of the derivative is affected by the value of the underlying
financial products:
N/A
For that derivative: -
Parties to the derivative: N/A
If the director or senior manager is not a party to the
derivative, the nature of the relevant interest in the
derivative:
N/A

Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: 1
Details of transactions requiring disclosure -
Date of transaction: 22 June 2021
Nature of transaction: Acquisition of 2,155 ordinary
shares in Oceania Healthcare
Limited in accordance with the
Dividend Reinvestment Plan 2019
Name of any other party or parties to the transaction (if
known):

The consideration, expressed in New Zealand dollars, paid
or received for the acquisition or disposal. If the
consideration was not in cash and cannot be readily
converted into a cash value, describe the consideration:
$3,026.98
Number of financial products to which the transaction
related:
2,155
If the issuer has a financial products trading policy that
prohibits directors or senior managers from trading during
any period without written clearance (a closed period)
include the following details -

Whether relevant interests were acquired or disposed of
during a closed period:
No
Whether prior written clearance was provided to allow the
acquisition or disposal to proceed during the closed period:
N/A
Date of the prior written clearance (if any): N/A

Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products: Ordinary shares
Nature of relevant interest:
Beneficial interest in shares
issued under the terms of the
Oceania Healthcare Employee
Share Scheme, under which
shares are held by OCA
Employees Trustee Limited
For that relevant interest -
Number held in class: 1,546
Current registered holder(s): OCA Employees Trustee Limited

For a derivative relevant interest -
Type of derivative: N/A
Details of derivative -
The notional value of the derivative (if any) or the notional
amount of underlying financial products (if any):
N/A
A statement as to whether the derivative is cash settled or
physically settled:
N/A
Maturity date of the derivative (if any): N/A
Expiry date of the derivative (if any): N/A
The price’s specified terms (if any): N/A
Any other details needed to understand how the amount of
the consideration payable under the derivative or the value
of the derivative is affected by the value of the underlying
financial products:
N/A
For that derivative relevant interest:
Parties to the derivative: N/A
If the director or senior manager is not a party to the
derivative, the nature of the relevant interest in the
derivative:
N/A

Certification
I certify that, to the best of my knowledge and belief, the
information contained in this disclosure is correct and that I
am duly authorised to make this disclosure by all persons
for whom it is made.

Signature of director or officer:

Date of signature: 29 June 2021
or
Signature of person authorised to sign on behalf of director
or officer:

Date of signature:
Name and title of authorised person:

---

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and ASX
Name of listed issuer: Oceania Healthcare Limited
Date this disclosure made: 29 June 2021
Date of last disclosure: 18 May 2021

Director or senior manager giving disclosure
Full name(s): Kathryn Waugh
Name of listed issuer: Oceania Healthcare Limited
Name of related body corporate (if applicable): N/A
Position held in listed issuer: Chief Financial Officer

Summary of acquisition or disposal of relevant interest (excluding derivatives)
Class of affected quoted financial products: Ordinary shares
Nature of the affected relevant interest(s):
Registered and beneficial owner
of shares acquired pursuant to the
Dividend Reinvestment Plan 2019
For that relevant interest -
Number held in class before acquisition or disposal: 11,834
Number held in class after acquisition or disposal: 11,952
Current registered holder(s): New share issue
Registered holder(s) once transfers are registered: Kathryn Waugh

Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative: N/A
Class of underlying financial products: N/A
Details of affected derivative -
The notional value of the derivative (if any) or the notional
amount of underlying financial products (if any):
N/A
A statement as to whether the derivative is cash settled or
physically settled:
N/A
Maturity date of the derivative (if any): N/A
Expiry date of the derivative (if any): N/A
The price specified in the terms of the derivative (if any): N/A

Any other details needed to understand how the amount of
the consideration payable under the derivative or the value
of the derivative is affected by the value of the underlying
financial products:
N/A
For that derivative: -
Parties to the derivative: N/A
If the director or senior manager is not a party to the
derivative, the nature of the relevant interest in the
derivative:
N/A

Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: 1
Details of transactions requiring disclosure -
Date of transaction: 22 June 2021
Nature of transaction: Acquisition of 118 ordinary shares
in Oceania Healthcare Limited in
accordance with the Dividend
Reinvestment Plan 2019
Name of any other party or parties to the transaction (if
known):

The consideration, expressed in New Zealand dollars, paid
or received for the acquisition or disposal. If the
consideration was not in cash and cannot be readily
converted into a cash value, describe the consideration:
$166.50
Number of financial products to which the transaction
related:
118
If the issuer has a financial products trading policy that
prohibits directors or senior managers from trading during
any period without written clearance (a closed period)
include the following details -

Whether relevant interests were acquired or disposed of
during a closed period:
No
Whether prior written clearance was provided to allow the
acquisition or disposal to proceed during the closed period:
N/A
Date of the prior written clearance (if any): N/A

Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products: Ordinary shares
Nature of relevant interest:
Beneficial interest in shares
issued under the terms of the
Oceania Healthcare Employee
Share Scheme
For that relevant interest -
Number held in class: 1,546
Current registered holder(s): OCA Employees Trustee Limited
For a derivative relevant interest -

Type of derivative: N/A
Details of derivative -
The notional value of the derivative (if any) or the notional
amount of underlying financial products (if any):
N/A
A statement as to whether the derivative is cash settled or
physically settled:
N/A
Maturity date of the derivative (if any): N/A
Expiry date of the derivative (if any): N/A
The price’s specified terms (if any): N/A
Any other details needed to understand how the amount of
the consideration payable under the derivative or the value
of the derivative is affected by the value of the underlying
financial products:
N/A
For that derivative relevant interest:
Parties to the derivative: N/A
If the director or senior manager is not a party to the
derivative, the nature of the relevant interest in the
derivative:
N/A

Certification
I certify that, to the best of my knowledge and belief, the
information contained in this disclosure is correct and that I
am duly authorised to make this disclosure by all persons
for whom it is made.

Signature of director or officer:

Date of signature:
or
Signature of person authorised to sign on behalf of director
or officer:


Date of signature: 29 June 2021
Name and title of authorised person: Anna Thorburn
Group General Counsel

---

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and ASX
Name of listed issuer: Oceania Healthcare Limited
Date this disclosure made: 29 June 2021
Date of last disclosure: 2 March 2021

Director or senior manager giving disclosure
Full name(s): Earl Gasparich
Name of listed issuer: Oceania Healthcare Limited
Name of related body corporate (if applicable): N/A
Position held in listed issuer: Former Chief Executive Officer

Summary of acquisition or disposal of relevant interest (excluding derivatives)
Class of affected quoted financial products: Ordinary shares
Nature of the affected relevant interest(s):
Beneficial interest in shares
acquired pursuant to the Dividend
Reinvestment Plan 2019
For that relevant interest -
Number held in class before acquisition or disposal: 2,114,109
Number held in class after acquisition or disposal: 2,135,295
Current registered holder(s): New share issue
Registered holder(s) once transfers are registered: Earl Gasparich, Celia Gasparich
and Carla Pearce as trustees of
the Gasparich Family Trust

Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative: N/A
Class of underlying financial products: N/A
Details of affected derivative -
The notional value of the derivative (if any) or the notional
amount of underlying financial products (if any):
N/A
A statement as to whether the derivative is cash settled or
physically settled:
N/A
Maturity date of the derivative (if any): N/A
Expiry date of the derivative (if any): N/A

The price specified in the terms of the derivative (if any): N/A
Any other details needed to understand how the amount of
the consideration payable under the derivative or the value
of the derivative is affected by the value of the underlying
financial products:
N/A
For that derivative: -
Parties to the derivative: N/A
If the director or senior manager is not a party to the
derivative, the nature of the relevant interest in the
derivative:
N/A

Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: 1
Details of transactions requiring disclosure -
Date of transaction: 22 June 2021
Nature of transaction: Acquisition of beneficial interest in
21,186 ordinary shares in
Oceania Healthcare Limited in
accordance with the Dividend
Reinvestment Plan 2019
Name of any other party or parties to the transaction (if
known):

The consideration, expressed in New Zealand dollars, paid
or received for the acquisition or disposal. If the
consideration was not in cash and cannot be readily
converted into a cash value, describe the consideration:
$29,745.51
Number of financial products to which the transaction
related:
21,186
If the issuer has a financial products trading policy that
prohibits directors or senior managers from trading during
any period without written clearance (a closed period)
include the following details -

Whether relevant interests were acquired or disposed of
during a closed period:
No
Whether prior written clearance was provided to allow the
acquisition or disposal to proceed during the closed period:
N/A
Date of the prior written clearance (if any): N/A

Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products: Ordinary shares
Nature of relevant interest: Beneficial interest in shares
issued under the terms of the
Oceania Healthcare Employee
Share Scheme, under which
shares are held by OCA
Employees Trustee Limited
For that relevant interest -

Number held in class: 1,546
Current registered holder(s): OCA Employees Trustee Limited
For a derivative relevant interest -
Type of derivative: N/A
Details of derivative -
The notional value of the derivative (if any) or the notional
amount of underlying financial products (if any):
N/A
A statement as to whether the derivative is cash settled or
physically settled:
N/A
Maturity date of the derivative (if any): N/A
Expiry date of the derivative (if any): N/A
The price’s specified terms (if any): N/A
Any other details needed to understand how the amount of
the consideration payable under the derivative or the value
of the derivative is affected by the value of the underlying
financial products:
N/A
For that derivative relevant interest:
Parties to the derivative: N/A
If the director or senior manager is not a party to the
derivative, the nature of the relevant interest in the
derivative:
N/A

Certification
I certify that, to the best of my knowledge and belief, the
information contained in this disclosure is correct and that I
am duly authorised to make this disclosure by all persons
for whom it is made.

Signature of director or officer:

Date of signature:
or
Signature of person authorised to sign on behalf of director
or officer:


Date of signature: 29 June 2021
Name and title of authorised person: Anna Thorburn
Group General Counsel

---

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and ASX
Name of listed issuer: Oceania Healthcare Limited
Date this disclosure made: 29 June 2021
Date of last disclosure: 4 June 2021

Director or senior manager giving disclosure
Full name(s): Jill Birch
Name of listed issuer: Oceania Healthcare Limited
Name of related body corporate (if applicable): N/A
Position held in listed issuer: Former GM Operations

Summary of acquisition or disposal of relevant interest (excluding derivatives)
Class of affected quoted financial products: Ordinary shares
Nature of the affected relevant interest(s):
Registered and beneficial owner
of shares acquired pursuant to the
Dividend Reinvestment Plan 2019
For that relevant interest -
Number held in class before acquisition or disposal: 529,467
Number held in class after acquisition or disposal: 534,772
Current registered holder(s): New share issue
Registered holder(s) once transfers are registered: Jill Birch

Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative: N/A
Class of underlying financial products: N/A
Details of affected derivative -
The notional value of the derivative (if any) or the notional
amount of underlying financial products (if any):
N/A
A statement as to whether the derivative is cash settled or
physically settled:
N/A
Maturity date of the derivative (if any): N/A
Expiry date of the derivative (if any): N/A
The price specified in the terms of the derivative (if any): N/A

Any other details needed to understand how the amount of
the consideration payable under the derivative or the value
of the derivative is affected by the value of the underlying
financial products:
N/A
For that derivative: -
Parties to the derivative: N/A
If the director or senior manager is not a party to the
derivative, the nature of the relevant interest in the
derivative:
N/A

Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: 1
Details of transactions requiring disclosure -
Date of transaction: 22 June 2021
Nature of transaction: Acquisition of 5,305 ordinary
shares in Oceania Healthcare
Limited in accordance with the
Dividend Reinvestment Plan 2019
Name of any other party or parties to the transaction (if
known):

The consideration, expressed in New Zealand dollars, paid
or received for the acquisition or disposal. If the
consideration was not in cash and cannot be readily
converted into a cash value, describe the consideration:
$7,449.60
Number of financial products to which the transaction
related:
5,305
If the issuer has a financial products trading policy that
prohibits directors or senior managers from trading during
any period without written clearance (a closed period)
include the following details -

Whether relevant interests were acquired or disposed of
during a closed period:
No
Whether prior written clearance was provided to allow the
acquisition or disposal to proceed during the closed period:
N/A
Date of the prior written clearance (if any): N/A

Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products: Ordinary shares
Nature of relevant interest:
Beneficial interest in shares
issued under the terms of the
Oceania Healthcare Employee
Share Scheme
For that relevant interest -
Number held in class: 1,546
Current registered holder(s): OCA Employees Trustee Limited
For a derivative relevant interest -

Type of derivative: N/A
Details of derivative -
The notional value of the derivative (if any) or the notional
amount of underlying financial products (if any):
N/A
A statement as to whether the derivative is cash settled or
physically settled:
N/A
Maturity date of the derivative (if any): N/A
Expiry date of the derivative (if any): N/A
The price’s specified terms (if any): N/A
Any other details needed to understand how the amount of
the consideration payable under the derivative or the value
of the derivative is affected by the value of the underlying
financial products:
N/A
For that derivative relevant interest:
Parties to the derivative: N/A
If the director or senior manager is not a party to the
derivative, the nature of the relevant interest in the
derivative:
N/A

Certification
I certify that, to the best of my knowledge and belief, the
information contained in this disclosure is correct and that I
am duly authorised to make this disclosure by all persons
for whom it is made.

Signature of director or officer:

Date of signature:
or
Signature of person authorised to sign on behalf of director
or officer:


Date of signature: 29 June 2021
Name and title of authorised person: Anna Thorburn
Group General Counsel